• Shuji Arita, Tsuyoshi Shirakawa, Yuzo Matsushita, Hozumi Kumagai Shimokawa, Gen Hirano, Akitaka Makiyama, Yoshihiro Shibata, Shingo Tamura, Taito Esaki, Kenji Mitsugi, Hiroshi Ariyama, Hitoshi Kusaba, Koichi Akashi, and Eishi Baba.
• Department of Comprehensive Clinical Oncology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan Department of Hematology and Medical Oncology, Kyushu University Hospital, Fukuoka, Japan.
• Anticancer Res. 2016 Apr 1; 36 (4): 1959-66.

BackgroundTAS-102 is an anti-metabolite which demonstrated activity against multidrug-resistant advanced colorectal cancer. Its major toxicities are hematological disorders.Patients And MethodsBackground, TAS-102 efficacy, toxicities and outcomes for patients with multidrug-resistant advanced colorectal cancer from six Institutions of the Kyushu Medical Oncology Group were retrospectively surveyed.ResultsForty-three patients, including fragile patients due to declining performance status and other comorbidities (37%) were analyzed. Efficacy was reflected in an objective overall response of 3%, median progression-free survival of 74 days (2.5 months) and median overall survival of 229 days (7.6 months). The most frequent Common Terminology Criteria for Adverse Events grade 3/4 adverse events were neutropenia (44%), leukopenia (26%) and anemia (23%). Febrile neutropenia was found in 7%. Sub-group analysis demonstrated an improved outcome on treatment with the sequence regorafenib-TAS-102.ConclusionTAS-102 was safely administered to modestly fragile patients with equivalent efficacy to that for the non-fragile population. Further investigation of sequential treatment using regorafenib and TAS-102 is needed.Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

43 keywords...

hide…